Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: Patient-reported outcome results of a randomised phase 3 trial Academic Article Article uri icon

Overview

MeSH Major

  • Computational Biology
  • Germ-Line Mutation
  • Neoplasms

abstract

  • Abiraterone plus prednisone delays patient-reported pain progression and HRQoL deterioration in chemotherapy-naive patients with metastatic castration-resistant prostate cancer. These results provide further support for the efficacy of abiraterone in this population.

publication date

  • November 2013

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1016/S1470-2045(13)70424-8

PubMed ID

  • 24075621

Additional Document Info

start page

  • 1193

end page

  • 9

volume

  • 14

number

  • 12